JP2020503885A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503885A5 JP2020503885A5 JP2019538535A JP2019538535A JP2020503885A5 JP 2020503885 A5 JP2020503885 A5 JP 2020503885A5 JP 2019538535 A JP2019538535 A JP 2019538535A JP 2019538535 A JP2019538535 A JP 2019538535A JP 2020503885 A5 JP2020503885 A5 JP 2020503885A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- antigen receptor
- chimeric antigen
- seq
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 29
- 210000001744 T-lymphocyte Anatomy 0.000 claims 10
- 210000000822 natural killer cell Anatomy 0.000 claims 10
- 150000007523 nucleic acids Chemical group 0.000 claims 9
- 230000004913 activation Effects 0.000 claims 7
- 230000003834 intracellular effect Effects 0.000 claims 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 101100508818 Mus musculus Inpp5k gene Proteins 0.000 claims 2
- 101100366438 Rattus norvegicus Sphkap gene Proteins 0.000 claims 2
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- REAQAWSENITKJL-DDWPSWQVSA-N Ala-Met-Asp-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O REAQAWSENITKJL-DDWPSWQVSA-N 0.000 claims 1
- 101000738335 Homo sapiens T-cell surface glycoprotein CD3 zeta chain Proteins 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 101100378956 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) AMD2 gene Proteins 0.000 claims 1
- 102100037906 T-cell surface glycoprotein CD3 zeta chain Human genes 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023004031A JP7700159B2 (ja) | 2017-01-18 | 2023-01-13 | Ａｘｌまたはｒｏｒ２に対するキメラ抗原受容体およびその使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762447898P | 2017-01-18 | 2017-01-18 | |
| US62/447,898 | 2017-01-18 | ||
| US201762467059P | 2017-03-03 | 2017-03-03 | |
| US62/467,059 | 2017-03-03 | ||
| US201762530193P | 2017-07-08 | 2017-07-08 | |
| US62/530,193 | 2017-07-08 | ||
| PCT/US2018/014122 WO2018136570A1 (en) | 2017-01-18 | 2018-01-17 | Chimeric antigen receptors against axl or ror2 and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023004031A Division JP7700159B2 (ja) | 2017-01-18 | 2023-01-13 | Ａｘｌまたはｒｏｒ２に対するキメラ抗原受容体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503885A JP2020503885A (ja) | 2020-02-06 |
| JP2020503885A5 true JP2020503885A5 (enExample) | 2021-03-04 |
| JP7280827B2 JP7280827B2 (ja) | 2023-05-24 |
Family
ID=61157332
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538535A Active JP7280827B2 (ja) | 2017-01-18 | 2018-01-17 | Ａｘｌまたはｒｏｒ２に対するキメラ抗原受容体およびその使用方法 |
| JP2023004031A Active JP7700159B2 (ja) | 2017-01-18 | 2023-01-13 | Ａｘｌまたはｒｏｒ２に対するキメラ抗原受容体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023004031A Active JP7700159B2 (ja) | 2017-01-18 | 2023-01-13 | Ａｘｌまたはｒｏｒ２に対するキメラ抗原受容体およびその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12187801B2 (enExample) |
| EP (1) | EP3571229A1 (enExample) |
| JP (2) | JP7280827B2 (enExample) |
| KR (2) | KR20260006705A (enExample) |
| CN (1) | CN110177808A (enExample) |
| AU (1) | AU2018211081B2 (enExample) |
| BR (1) | BR112019014615A2 (enExample) |
| CA (1) | CA3049674A1 (enExample) |
| IL (1) | IL267902B2 (enExample) |
| MX (1) | MX2019008503A (enExample) |
| SG (2) | SG10202107808SA (enExample) |
| TW (1) | TWI860971B (enExample) |
| WO (1) | WO2018136570A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3186284T3 (da) | 2014-08-28 | 2022-05-09 | Bioatla Inc | Betinget aktive kimæriske antigenreceptorer til modificerede t-celler |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| US12590321B2 (en) | 2016-03-19 | 2026-03-31 | Exuma Biotech Corp. | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof |
| WO2021178701A1 (en) * | 2020-03-05 | 2021-09-10 | Exuma Biotech Corp. | Methods and compositions for the delivery of modified lymphocyte aggregates |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| WO2020047527A2 (en) * | 2018-09-02 | 2020-03-05 | F1 Bioventures, Llc | Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs |
| EP4656204A3 (en) * | 2016-04-15 | 2026-06-03 | BioAtla, Inc. | Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof |
| EP4122958A1 (en) | 2016-05-13 | 2023-01-25 | BioAtla, Inc. | Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| SG10202107808SA (en) | 2017-01-18 | 2021-08-30 | F1 Oncology Inc | Chimeric antigen receptors against axl or ror2 and methods of use thereof |
| CN112823166B (zh) * | 2018-09-07 | 2025-01-24 | 生物蛋白有限公司 | 用于修饰的t细胞的条件活性嵌合抗原受体 |
| CN111378040B (zh) * | 2018-12-29 | 2021-08-10 | 深圳大学 | 检测多种恶性肿瘤细胞的抗体及其应用 |
| CN111378039B (zh) | 2018-12-29 | 2021-08-24 | 深圳大学 | 治疗恶性肿瘤的抗体及其应用 |
| EP3936523A4 (en) * | 2019-01-08 | 2022-09-07 | Shenzhen University | DETECTION OF ANTIBODIES AGAINST MALIGNANT TUMOR CELLS AND THEIR USES |
| EP3715368A1 (en) | 2019-03-28 | 2020-09-30 | Albert-Ludwigs-Universität Freiburg | Chimeric antigen receptors, vectors coding for such receptors and their use in the modification of t cells |
| WO2020219843A1 (en) * | 2019-04-26 | 2020-10-29 | The University Of North Carolina At Chapel Hill | Chimeric antigen receptor constructs and their use in car-t cells |
| CN110317277A (zh) * | 2019-07-10 | 2019-10-11 | 杭州普科亭生物医药有限公司 | 嵌合抗原受体及其应用 |
| CN112390894A (zh) * | 2019-08-12 | 2021-02-23 | 广东东阳光药业有限公司 | 嵌合抗原受体及其应用 |
| CN112500492B (zh) * | 2019-09-13 | 2023-08-04 | 中国科学院分子细胞科学卓越创新中心 | 一种嵌合抗原受体及其用途 |
| US12643947B2 (en) * | 2019-11-18 | 2026-06-02 | The Regents Of The University Of California | Anti-ROR-2 antibodies and methods of use |
| CN115485293A (zh) * | 2020-01-23 | 2022-12-16 | 埃克苏马生物技术公司 | 用于her2的嵌合抗原受体和其使用方法 |
| CN114075548B (zh) * | 2020-08-13 | 2023-11-21 | 广州医科大学附属第二医院 | 一种靶向axl的car-t细胞及其制备方法和应用 |
| US12365873B2 (en) | 2021-01-28 | 2025-07-22 | Allogene Therapeutics, Inc. | Methods for transducing immune cells |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| CN115125272B (zh) * | 2021-03-29 | 2024-04-19 | 复旦大学 | 一种car-t治疗载体及其构建方法和应用 |
| CN116102658B (zh) * | 2021-11-09 | 2025-04-29 | 四川大学华西医院 | 基于gas6构建的嵌合抗原受体免疫细胞制备及其应用 |
| CN115927477A (zh) * | 2022-10-18 | 2023-04-07 | 华中科技大学同济医学院附属协和医院 | 一种用于检测人源化car-t抗car抗体的方法 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| TW197439B (enExample) | 1991-04-04 | 1993-01-01 | Ueno Pharmaceutics Applic Res Co Ltd | |
| ATE237694T1 (de) | 1991-08-20 | 2003-05-15 | Us Gov Health & Human Serv | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| US5283253A (en) | 1991-09-23 | 1994-02-01 | Florida State University | Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| WO1993010076A1 (en) | 1991-11-22 | 1993-05-27 | The University Of Mississippi | Synthesis and optical resolution of the taxol side chain and related compounds |
| US5200534A (en) | 1992-03-13 | 1993-04-06 | University Of Florida | Process for the preparation of taxol and 10-deacetyltaxol |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| AU4242993A (en) | 1992-05-21 | 1993-12-13 | Penn State Research Foundation, The | Cultured (taxus) tissues as a source of taxol, related taxanes and other novel anti-tumor/anti-viral compounds |
| US5274137A (en) | 1992-06-23 | 1993-12-28 | Nicolaou K C | Intermediates for preparation of taxols |
| US5294637A (en) | 1992-07-01 | 1994-03-15 | Bristol-Myers Squibb Company | Fluoro taxols |
| US5202448A (en) | 1992-08-14 | 1993-04-13 | Napro Biotherapeutics, Inc. | Processes of converting taxanes into baccatin III |
| CA2100808A1 (en) | 1992-10-01 | 1994-04-02 | Vittorio Farina | Deoxy paclitaxels |
| FR2696461B1 (fr) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent. |
| FR2696458B1 (fr) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | Procédé de préparation de dérivés du taxane. |
| FR2696463B1 (fr) | 1992-10-05 | 1994-11-25 | Rhone Poulenc Rorer Sa | Procédé d'obtention de la désacétyl-10 baccatine III. |
| FR2696462B1 (fr) | 1992-10-05 | 1994-11-25 | Rhone Poulenc Rorer Sa | Procédé d'obtention de la désacétyl-10 baccatine III. |
| FR2696464B1 (fr) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III. |
| EP0673431A1 (en) | 1992-12-03 | 1995-09-27 | Genzyme Corporation | Gene therapy for cystic fibrosis |
| US5279949A (en) | 1992-12-07 | 1994-01-18 | Board Of Trustees Operating Michigan State University | Process for the isolation and purification of taxol and taxanes from Taxus spp |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| US5824701A (en) | 1993-10-20 | 1998-10-20 | Enzon, Inc. | Taxane-based prodrugs |
| DE69435223D1 (de) | 1993-10-25 | 2009-09-03 | Canji Inc | Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung |
| US5415869A (en) | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
| SG119177A1 (en) | 1994-12-09 | 2006-02-28 | Imp College Innovations Ltd | Identification of genes |
| WO1998008833A1 (en) | 1996-08-26 | 1998-03-05 | Bristol-Myers Squibb Company | Sulfenamide taxane derivatives |
| AU739028B2 (en) | 1996-09-27 | 2001-10-04 | Bristol-Myers Squibb Company | Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells |
| WO1998022451A1 (en) | 1996-11-19 | 1998-05-28 | Daiichi Pharmaceutical Co., Ltd. | Taxol derivatives |
| US5977386A (en) | 1996-12-24 | 1999-11-02 | Bristol-Myers Squibb Company | 6-thio-substituted paclitaxels |
| IL133585A0 (en) | 1997-06-20 | 2001-04-30 | Baker Norton Pharma | Soluble prodrugs of paclitaxel |
| US7288665B1 (en) | 1997-08-18 | 2007-10-30 | Florida State University | Process for selective derivatization of taxanes |
| JPH1192468A (ja) | 1997-09-17 | 1999-04-06 | Yakult Honsha Co Ltd | 新規なタキサン誘導体 |
| WO1999018113A1 (fr) | 1997-10-08 | 1999-04-15 | Bio Research Corporation Of Yokohama | Derives taxoides et leur procede de production |
| GB0105924D0 (en) | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
| EP1382969A1 (en) | 2002-07-17 | 2004-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Diagnosis and prevention of cancer cell invasion |
| BRPI0820073A2 (pt) | 2007-11-12 | 2015-06-23 | U3 Pharma Gmbh | Anticorpos anti-axl |
| CN101918452A (zh) | 2007-11-15 | 2010-12-15 | 中外制药株式会社 | 与Anexelekto结合的单克隆抗体及其利用 |
| MX355507B (es) | 2009-03-09 | 2018-04-19 | Bioatla Llc | Proteinas mirac. |
| TW201106972A (en) | 2009-07-27 | 2011-03-01 | Genentech Inc | Combination treatments |
| JP5956342B2 (ja) | 2009-11-03 | 2016-07-27 | シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ | 形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ） |
| CN103080136B (zh) | 2010-06-18 | 2015-08-12 | 霍夫曼-拉罗奇有限公司 | 抗Axl抗体及使用方法 |
| AU2012273955A1 (en) | 2011-06-22 | 2014-01-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-Axl antibodies and uses thereof |
| US20140322234A1 (en) | 2012-01-03 | 2014-10-30 | The Board Of Trustees Of The Leland Stanford Junior University | Analysis and Targeting of ROR2 in Cancer |
| EP2997134B1 (en) * | 2013-05-14 | 2020-06-24 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| US11111288B2 (en) * | 2014-08-28 | 2021-09-07 | Bioatla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
| DK3186284T3 (da) * | 2014-08-28 | 2022-05-09 | Bioatla Inc | Betinget aktive kimæriske antigenreceptorer til modificerede t-celler |
| WO2016142768A1 (en) * | 2015-03-10 | 2016-09-15 | Eureka Therapeutics, Inc. | Ror2 antibody |
| EP3098237B1 (en) * | 2015-05-28 | 2018-08-01 | Universität Zu Köln | Anti-toso chimeric antigen receptor and its use |
| CA3003399A1 (en) | 2015-11-02 | 2017-05-11 | Bioatla, Llc | Conditionally active polypeptides |
| EP4656204A3 (en) | 2016-04-15 | 2026-06-03 | BioAtla, Inc. | Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof |
| MX2019002199A (es) * | 2016-08-31 | 2019-05-16 | Bioatla Llc | Polipeptidos condicionalmente activos y métodos para generarlos. |
| SG10202107808SA (en) | 2017-01-18 | 2021-08-30 | F1 Oncology Inc | Chimeric antigen receptors against axl or ror2 and methods of use thereof |
-
2018
- 2018-01-17 SG SG10202107808SA patent/SG10202107808SA/en unknown
- 2018-01-17 WO PCT/US2018/014122 patent/WO2018136570A1/en not_active Ceased
- 2018-01-17 IL IL267902A patent/IL267902B2/en unknown
- 2018-01-17 JP JP2019538535A patent/JP7280827B2/ja active Active
- 2018-01-17 AU AU2018211081A patent/AU2018211081B2/en active Active
- 2018-01-17 BR BR112019014615-6A patent/BR112019014615A2/pt active Search and Examination
- 2018-01-17 MX MX2019008503A patent/MX2019008503A/es unknown
- 2018-01-17 CN CN201880007323.XA patent/CN110177808A/zh active Pending
- 2018-01-17 KR KR1020257042953A patent/KR20260006705A/ko active Pending
- 2018-01-17 KR KR1020197024098A patent/KR102905343B1/ko active Active
- 2018-01-17 SG SG11201906468TA patent/SG11201906468TA/en unknown
- 2018-01-17 CA CA3049674A patent/CA3049674A1/en active Pending
- 2018-01-17 EP EP18703143.0A patent/EP3571229A1/en active Pending
- 2018-01-17 US US16/478,360 patent/US12187801B2/en active Active
- 2018-01-18 TW TW107101870A patent/TWI860971B/zh active
-
2023
- 2023-01-13 JP JP2023004031A patent/JP7700159B2/ja active Active
-
2024
- 2024-10-04 US US18/907,457 patent/US20250026840A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021534770A5 (enExample) | ||
| WO2021008610A1 (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| JP2019528077A5 (enExample) | ||
| JP2023518134A5 (enExample) | ||
| JP2024023228A5 (enExample) | ||
| JP2020512820A5 (enExample) | ||
| JP2016533174A5 (enExample) | ||
| MX2023005420A (es) | Anticuerpo bcma humanizado y linfocitos t car-bcma. | |
| JP2020517287A5 (enExample) | ||
| JP2022512684A5 (enExample) | ||
| JP2021525530A5 (enExample) | ||
| JP2020517294A5 (enExample) | ||
| JP2019515666A5 (enExample) | ||
| JP2017504578A5 (enExample) | ||
| JP2021512614A5 (enExample) | ||
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| JP2018528786A5 (enExample) | ||
| JP2017522891A5 (enExample) | ||
| JP2014518615A5 (enExample) | ||
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| TWI690539B (zh) | 一個需依賴標靶細胞使T細胞接合及活化之不對稱異二聚Fc-ScFv融合抗體形式及其在癌症治療上之應用 | |
| JP2024527020A5 (enExample) | ||
| JP2022529380A5 (enExample) | ||
| JP2024515919A5 (enExample) | ||
| RU2018129169A (ru) | Грызуны, имеющие сконструированный участок разнообразия тяжелой цепи |